News

CMN Weekly (20 May 2022) - Your Weekly CRISPR Medicine News

Some of the best links we picked up around the internet

By: Gorm Palmgren - May. 20, 2022

Top picks

Research

Industry

News from ASGCT

Detection

Reviews

Regulation and opinion

News from CRISPR Medicine News

  • Monday's feature was about the successful use of CRISPR-Cas9 to selectively disrupt a mutant PSEN1 allele that causes familial Alzheimer’s disease. We interviewed Evangelos Konstantinidis, the first author of the proof-of-concept study, showing that gene editing in human fibroblasts may reverse Alzheimer's disease phenotypes by reducing the accumulation of extracellular amyloid-β deposits.
  • On Wednesday, the clinical update reported on a new base-editing cholesterol-reducing therapy that has been approved for a clinical trial in New Zealand. The treatment, VERVE-101, is developed by Verve Therapeutics.
  • Our sister-site CRISPR AgroBio News (CARBON) launched its bi-weekly newsletter on Tuesday with links to recent news from CRISPR in agriculture. The top story was the introduction of a single base mutation in SOC1 in lettuce that delayed bolting, i.e., when crops put on a vertical growth spurt to flower and set seed before the vegetables are ready for harvest.

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN Weekly

News: CMN Weekly (20 May 2022) - Your Weekly CRISPR Medicine News
Search your next CRISPR job here...
Search your next CRISPR job here...
CLINICAL TRIALS
IND Enabling
Phase I
Phase II
Phase III
T-cell Acute Lymphoid Leukaemia, ALL, (NCT05397184)
Sponsors:
Great Ormond Street Hospital for Children NHS Foundation Trust
Indicator
IND Enabling
Phase I
Phase II
Phase III
Solid tumors, (NCT05361174)
Sponsors:
Iovance Biotherapeutics, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine